Search

The study aimed to investigate the impact of astaxanthin on the hepatic health in juvenile Anguilla rostrata under histamine stress. Four hundred juvenile fish with an initial weight of (25.01 ± 0.17) g were randomly divided into four groups (with four replicates per group and 25 fish per replicate): CK group, H group, H+AST4 group, and H+AST8 group. The juvenile fish were fed a basal feed, high histamine feed, and high histamine feed supplemented with 4 or 8 mg/kg of astaxanthin, respectively. The experiment lasted for 70 days. The results showed that compared to the CK group, the H group exhibited elevated serum AST and ALT activities (P<0.05). The hepatic SOD, CAT, GSH-Px activities, GSH concentration, and T-AOC decreased (P<0.05), while the MDA concentration increased in the H group (P<0.05). In the H+AST4 group and H+AST8 group, the serum AST and ALT activities were significantly lower than those in the H group (P<0.05), and the hepatic SOD, CAT, GSH-Px activities, GSH concentration, and T-AOC were higher than those in the H group (P<0.05), while the MDA concentration was lower than those in the H group (P<0.05). Compared to the CK group, the H group exhibited blurred cell boundaries, incomplete hepatic lobule structure, and numerous hepatocytes with nuclear displacement and vacuolar degeneration. The H+AST4 group and H+AST8 group showed clear cell boundaries, polygonal shapes, large and round nuclei centrally located, with no significant changes compared to the CK group. The study indicates that adding 4 mg/kg of astaxanthin to the feed under histamine stress can reduce serum aminotransferase activity and hepatic MDA concentrations, enhance hepatic antioxidant capacity, and improve hepatic structure, benefiting hepatic health. Adding 8 mg/kg of astaxanthin does not further improve the above indicators in juvenile Anguilla rostrata. [ABSTRACT FROM AUTHOR]

Aim: To obtain a correlation between HER-2 expression and the clinicopathological features incolorectal cancers. (CRCs) using a meta.analysis based approach.Materials and Methods: Electronic databases and reference lists were searched for relevant published studies. After inclusion and exclusion criteria were applied, case and control studies related to research topic were included in present meta-analysis. Data analysis was performed using Comprehensive Meta Analysis. (CMA) 2.0 software.Result: A total of 30 studies comprising 4,942 CRC patients and 521 healthy controls met the inclusion criteria. Our major results implied that the expression level of HER-2 was significantly higher in CRC patients than healthy controls (odds ratio (OR) = 10.436, 95% confidence interval (CI) = 5.498-19.810, P < 0.001). Sample stratification based on Dukes stages suggested that increased expression level of HER-2 protein was found in CRC patients with Dukes C/D compared with CRC patients with Dukes A/B (OR = 0.335, 95% CI = 0.198-0.568, P < 0.001). The current meta-analysis also found that, in CRC patients with lymph node metastasis (LNM), the HER-2 expression was significantly higher than that in CRC patients without LNM (OR = 1.987, 95%CI = 1.209-3.265, P = 0.007).Conclusion: Our meta-analysis study strongly suggests that HER-2 expression levels are clearly correlated with the clinicopathological features in CRC; therefore, HER-2 may be a potential biomarker for diagnosis and prognosis of CRC. [ABSTRACT FROM AUTHOR]

Aim: To investigate the correlation between human epidermal growth factor receptor (HER-2) protein expression and colorectal cancer (CRC) using a case-control study and meta-analysis., Methods: Tumor tissue specimens from 162 CRC patients were selected for the case group. Fifty cases were randomly selected, and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group. The expression of the HER-2 protein in the 162 CRC tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry. The experimental data were analyzed using SPSS 18.0 software, and R software version 3.1.0 was utilized for further verification., Results: The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens. The data showed that the expression of HER-2 in CRC was related to the Dukes' stage, the depth of invasion and lymph node metastasis. The HER-2-positive patients had lower 3- and 5-year OS rates than the HER-2-negative patients, but there was no significant difference. However, there was a statistically significant difference in the 3- and 5-year disease-free survival (DFS) rates of HER-2-positive and HER-2-negative patients. The results of the meta-analysis showed that the expression of HER-2 in CRC patients was statistically significantly increased over that of healthy people. The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients., Conclusion: Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy.